INmune Bio Inc. (INMB)
| Market Cap | 49.85M -67.5% |
| Revenue (ttm) | n/a +257.1% |
| Net Income | -41.60M |
| EPS | -1.61 |
| Shares Out | 26.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 765,815 |
| Open | 1.790 |
| Previous Close | 1.790 |
| Day's Range | 1.740 - 1.900 |
| 52-Week Range | 1.090 - 3.244 |
| Beta | 0.98 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+273.33%) |
| Earnings Date | Aug 6, 2026 |
About INMB
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatmen... [Read more]
Financial Performance
In 2025, INmune Bio's revenue was $50,000, an increase of 257.14% compared to the previous year's $14,000. Losses were -$45.93 million, 9.15% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for INMB stock is "Strong Buy." The 12-month stock price target is $7.0, which is an increase of 273.33% from the latest price.
News
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer's Disease at AAIC
Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF inhibition.
INmune Bio advances CORDStrom platform patent application in the U.S.
INmune Bio (INMB) announced that it has submitted its CORDStrom platform patent application into the U.S. national phase before the United States Patent and Trademark Office, or USPTO. Published first...
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
Secures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Program Ebstrocel for Epidermolysis Bullosa and Next-Generation Engineered Modalities Extending to 2045
INmune Bio receives MHRA approval for Ebstrocel pediatric investigation plan
INmune Bio (INMB) announced that the UK Medicines & Healthcare products Regulatory Agency, or MHRA, has approved the pediatric investigation plan, or PIP, for Ebstrocel for the treatment of Recessive…
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
Approval of pediatric strategy validates clinical data package and accelerates the regulatory path for CORDStrom™ in the United Kingdom
INmune Bio announces MHRA alignment in pre-MAA CORDStrom meeting
INmune Bio (INMB) announced that it has received official, accepted meeting minutes from its recent face-to-face pre-Marketing Authorization Application, or pre-MAA, Scientific Advice meeting with the...
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
MHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions covering CMC, non-clinical and clinical evidence packages MHRA pediatric feedback recognizes Mission...
INmune Bio Transcript: AGM 2026
The meeting addressed board elections, auditor ratification, and an amended stock incentive plan, all of which were approved by stockholders. A quorum was present, and final voting results will be filed with the SEC. Stockholders participated in a Q&A session.
INmune Bio reports positive MRI data in Phase 2 Alzheimer’s trial
INmune Bio (INMB) announced positive results from exploratory MRI imaging analyses of its MINDFuL Phase 2 trial of XPro in patients with early Alzheimer’s disease. “A statistically significant treatme...
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200), demonstrating broad tissue-level target engagement and treatment-related biological effect.
INmune Bio Slides: Corporate presentation
INmune Bio has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
INmune Bio publishes MINDFuL trial results in NPJ Dementia
INmune Bio (INMB) announced that results from its Phase 2 MINDFuL trial in Alzheimer’s disease have been published in the peer-reviewed journal NPJ Dementia. The study evaluated the safety, biomarker…
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
Boca Raton, FL, May 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing therapies that target innate immune dysfunction, today announced that...
INmune Bio receives fast track designation from FDA for XPro
INmune Bio (INMB) announced that the FDA has granted fast track designation to XPro, the company’s selective soluble TNF inhibitor, for the treatment of early Alzheimer’s disease. The designation spec...
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
BOCA RATON, FL, May 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced that the U.S. Food and Drug ...
INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point
Alliance launches with 26 founding companies to develop a national strategy for U.S. biotechnology leadership BOCA RATON, Fla., May 13, 2026 (GLOBE NEWSWIRE) -- INmune Bio, a clinical-stage biotechnol...
INmune Bio Earnings Call Transcript: Q1 2026
Q1 2026 saw reduced net loss and R&D expenses, with $21.4M in cash supporting operations into 2027. Regulatory and manufacturing milestones for CORDStrom are progressing, while XPro advances with new imaging data and partnership exploration.
INmune Bio Earnings release: Q1 2026
INmune Bio released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
INmune Bio Quarterly report: Q1 2026
INmune Bio has published its Q1 2026 quarterly earnings report on May 7, 2026.
INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update
BOCA RATON, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's inna...
INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases
LONDON, UK and BOCA RATON, FL, May 05, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune Bio”), a clinical-stage biotechnology company, and Anthony Nolan, a pioneering UK-based charity ...
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage infla...
INmune Bio Proxy statement: Proxy filing
INmune Bio filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
INmune Bio announces new preclinical data for INB03
INmune Bio (INMB) announces new preclinical data for INB03. The data will be presented at the American Association for Cancer Research, AACR, Annual Meeting 2026 in San Diego on April…
INmune Bio Earnings Call Transcript: Q4 2025
Advanced CORDStrom for RDEB towards regulatory filings, completed phase II trials for XPro in Alzheimer's and INKmune in prostate cancer, and raised $27.5M in equity. Cash runway extends through Q1 2027, with key regulatory milestones expected in 2026–2027.